The manufacturer of Seroxat® has written to healthcare professionals in December 2024 and advised that this product will be discontinued in 2025.
Seroxat® suspension was discontinued in October 2022. The tablets have been discontinued for commercial reasons, there are no safety concerns. The three strengths will all be discontinued; the 20mg in March 2025, the 30mg in May 2025 and the 10mg in November 2025. The phased discontinuation is likely due to existing stock in the supply chain.
There are currently several generic suppliers of the tablets and this discontinuation is expected to only affect patients issued branded prescriptions.
Action: Clinicians should be aware of this product being discontinued. It would be prudent to run clinical system searches to identify any patients who are currently prescribed this product to assess if a suitable alternative can be arranged.